Today: 8 July 2026
Browse Category

SWX:ROP 10 June 2026

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Holding Ltd. participation certificates listed on SIX traded up 1.07% at CHF 322.20 late Wednesday morning. Investors were eyeing a new $2.3 billion deal with Nurix Therapeutics, bringing Roche a late-stage blood-cancer asset. The stock line now trades as ROP after the company switched from the former ROG Genussscheine in March. Roche’s bearer shares are listed as RO. The Swiss Market Index edged higher, gaining roughly 0.35% to 13,403.50. The SMI tracks Switzerland’s top 20 blue chips by size and liquidity, recalculating in real time as stocks change hands.
10 June 2026
··

Stock Market Today

  • AstraZeneca (LSE:AZN) Seen 13% Below Fair Value as Oncology Deals Expand
    July 8, 2026, 12:54 PM EDT. AstraZeneca (LSE:AZN) is trading at £143.64, nearly 13% under a fair value estimate of £164.85. The drugmaker's growing push in oncology and siRNA partnerships and a late-stage pipeline in cancer, rare diseases, and heart drugs are seen driving more than $10 billion in potential risk-adjusted peak sales. Shares are up 3.65% over 30 days but down 5.6% over the last 90 days. Total shareholder return for one year is solid at 41.34%. Key risks include pricing pressure and heavy reliance on blockbuster drugs, both of which could weigh on valuation. AstraZeneca trades at 28.7x earnings, well above the sector average of 12.3x, pricing in hopes for further growth.
Go toTop